The merger was put together at a troubled time for biotech. To help ensure the merged company wouldn't be subjects to a potential delisting due to its stock price a potential 3-4 to 1 reverse-spilt was proposed. They needed a strong reverse-split to 'guarentee' they wouldn't soon be up for delisting. Markets can act bad to a reserve-split. Add that on top of the information vacuum we are in and and you have a double whammy. The insiders know about the forward-plan and the deals that have been discussed for AEZS's diagnostic and PGX, etc., but we as outsiders don't. There's also the risk that the merger doesn't go through complicating matters. Investors don't know for sure what it is they are investing in. Will the merger succeed? CZO's main client also disappeared as AEZS's revenue from its diagnostic test termorarily vanished. What is the revenue profile of the new company?
What if all the clouds lift and the uncertainty is removed? Ronnie is "thrilled" with what he sees.
AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide)
CZO's main client returns
AEZS's diagnostic continuing roll-out for adults
FDA approval for the test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up
Commissioning of 10X scale-up to decision point for mass industrialization of PGX
PGX licensing deal
Immune booster plant
Phase I avenanthramide clinical trial results
Wound healing results
Wound healing partnership
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision
